Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$60.10-1.8%$56.99$30.04▼$71.13$5.46B1.812.54 million shs1.13 million shsVRTXVertex Pharmaceuticals$390.45-0.2%$419.84$362.50▼$519.88$99.98B0.441.62 million shs636,745 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+5.79%+13.97%+2.44%+37.72%+28.17%VRTXVertex Pharmaceuticals-0.47%-1.29%-0.36%-12.72%-20.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$60.10-1.8%$56.99$30.04▼$71.13$5.46B1.812.54 million shs1.13 million shsVRTXVertex Pharmaceuticals$390.45-0.2%$419.84$362.50▼$519.88$99.98B0.441.62 million shs636,745 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+5.79%+13.97%+2.44%+37.72%+28.17%VRTXVertex Pharmaceuticals-0.47%-1.29%-0.36%-12.72%-20.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.47Hold$71.6019.14% UpsideVRTXVertex Pharmaceuticals 2.57Moderate Buy$496.0527.05% UpsideCurrent Analyst Ratings BreakdownLatest VRTX and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025VRTXVertex PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$510.00 ➝ $475.009/2/2025VRTXVertex PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform8/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/7/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $80.008/6/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$42.00 ➝ $56.008/6/2025VRTXVertex PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$424.00 ➝ $411.008/6/2025VRTXVertex PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$558.00 ➝ $546.008/6/2025VRTXVertex PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$460.008/5/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$82.008/5/2025CRSPCRISPR TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$38.00 ➝ $42.008/5/2025VRTXVertex PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$442.00 ➝ $438.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M146.49N/AN/A$22.64 per share2.65VRTXVertex Pharmaceuticals$11.02B9.08N/AN/A$63.72 per share6.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M$13.9927.8722.30N/A31.86%23.91%17.14%11/3/2025 (Estimated)Latest VRTX and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million8/4/2025Q2 2025VRTXVertex Pharmaceuticals$4.24$4.52+$0.28$3.99$2.90 billion$2.94 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A16.6116.61VRTXVertex PharmaceuticalsN/A2.522.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46090.95 million87.22 millionOptionableVRTXVertex Pharmaceuticals6,100256.39 million255.88 millionOptionableVRTX and CRSP HeadlinesRecent News About These CompaniesVertex Plunges Around 24% in Six Months: How to Play the Stock3 hours ago | zacks.comNew England Research & Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTXSeptember 17 at 7:08 AM | marketbeat.comCzech National Bank Has $27.95 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXSeptember 17 at 5:28 AM | marketbeat.comMassMutual Private Wealth & Trust FSB Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTXSeptember 17 at 5:18 AM | marketbeat.comWhy This Biotech Company Could Be a Growth Stock PowerhouseSeptember 17 at 5:10 AM | fool.comPaladin Wealth LLC Purchases Shares of 1,240 Vertex Pharmaceuticals Incorporated $VRTXSeptember 16 at 6:08 AM | marketbeat.comGradient Investments LLC Buys New Shares in Vertex Pharmaceuticals Incorporated $VRTXSeptember 16 at 5:30 AM | marketbeat.comE. Ohman J or Asset Management AB Has $4.68 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTXSeptember 16 at 5:30 AM | marketbeat.comGK Wealth Management LLC Purchases Shares of 689 Vertex Pharmaceuticals Incorporated $VRTXSeptember 16 at 5:20 AM | marketbeat.comModern Wealth Management LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTXSeptember 16 at 3:50 AM | marketbeat.com1 Reason Wall Street Is Obsessed With Vertex PharmaceuticalsSeptember 15 at 8:30 AM | fool.comVertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic PositioningSeptember 15 at 7:31 AM | tipranks.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by Cim LLCSeptember 15 at 5:18 AM | marketbeat.comAdvisors Capital Management LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTXSeptember 15 at 4:47 AM | marketbeat.comIntech Investment Management LLC Has $4.22 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXSeptember 15 at 4:31 AM | marketbeat.comIntegrity Alliance LLC. Makes New $445,000 Investment in Vertex Pharmaceuticals Incorporated $VRTXSeptember 15 at 4:20 AM | marketbeat.com9,601 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by AG2R LA Mondiale Gestion D ActifsSeptember 14 at 7:02 AM | marketbeat.comSwedbank AB Decreases Position in Vertex Pharmaceuticals Incorporated $VRTXSeptember 14 at 6:52 AM | marketbeat.comVoya Investment Management LLC Acquires 128,432 Shares of Vertex Pharmaceuticals Incorporated $VRTXSeptember 14 at 6:51 AM | marketbeat.comStrs Ohio Invests $37.74 Million in Vertex Pharmaceuticals Incorporated $VRTXSeptember 14 at 5:16 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by McAdam LLCSeptember 14 at 4:57 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRTX and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$60.10 -1.10 (-1.79%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Vertex Pharmaceuticals NASDAQ:VRTX$390.45 -0.91 (-0.23%) As of 01:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
